{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:09:07Z","timestamp":1762826947441,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":305,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology Practice"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.cnp.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T09:48:19Z","timestamp":1636278499000},"page":"281-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Multifocal myoclonus as a presentation of levetiracetam toxicity"],"prefix":"10.1016","volume":"6","author":[{"given":"Mei","family":"Bou Nasif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Varade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Z.","family":"Koubeissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cnp.2021.10.004_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","article-title":"Levetiracetam in the treatment of epilepsy","volume":"4","author":"Abou-Khalil","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.cnp.2021.10.004_b0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.yebeh.2007.05.006","article-title":"Accidental overdosage of levetiracetam in two children caused no side effects","volume":"11","author":"Awaad","year":"2007","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.cnp.2021.10.004_b0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1081\/CLT-120016959","article-title":"A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data","volume":"40","author":"Barrueto","year":"2002","journal-title":"J. Toxicol. Clin. Toxicol."},{"issue":"1","key":"10.1016\/j.cnp.2021.10.004_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.09.005","article-title":"Efficacy and safety of levetiracetam 1000\u20133000 mg\/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study","volume":"63","author":"Beran","year":"2005","journal-title":"Epilepsy Res."},{"issue":"4","key":"10.1016\/j.cnp.2021.10.004_b0025","first-page":"292","article-title":"Acute levetiracetam overdose presented with mild adverse events","volume":"19","author":"Chayasirisobhon","year":"2010","journal-title":"Acta Neurol. Taiwan"},{"issue":"4","key":"10.1016\/j.cnp.2021.10.004_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/pde.14179","article-title":"Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept","volume":"37","author":"Est\u00e9banez","year":"2020","journal-title":"Pediatr. Dermatol."},{"issue":"11","key":"10.1016\/j.cnp.2021.10.004_b0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/11319450-000000000-00000","article-title":"Pancytopenia associated with levetiracetam treatment","volume":"29","author":"Gallerani","year":"2009","journal-title":"Clin. Drug Invest."},{"issue":"5","key":"10.1016\/j.cnp.2021.10.004_b0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","article-title":"Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.cnp.2021.10.004_b0045","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e17","article-title":"Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008\u20132017","volume":"35","author":"Kim","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"10.1016\/j.cnp.2021.10.004_b0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2710.2012.01361.x","article-title":"Overdose with levetiracetam: a case report and review of the literature","volume":"38","author":"Larkin","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.cnp.2021.10.004_b0055","first-page":"137","article-title":"Two cases of levetiracetam overdose without any serious side effects","volume":"28","author":"Ozturk","year":"2017","journal-title":"Gazi Med. J."},{"issue":"2","key":"10.1016\/j.cnp.2021.10.004_b0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/15563650.2015.1115054","article-title":"Cardiovascular toxicity with levetiracetam overdose","volume":"54","author":"Page","year":"2016","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"11","key":"10.1016\/j.cnp.2021.10.004_b0065","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cnp.2021.10.004_b0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.seizure.2020.01.002","article-title":"Levetiracetam and cutaneous adverse reactions: A systematic review of descriptive studies","volume":"75","author":"Rashid","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.cnp.2021.10.004_b0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5582\/ddt.2016.01082","article-title":"Levetiracetam and topiramate poisoning: Two overdoses on those drugs with no lasting effects","volume":"11","author":"Sarfaraz","year":"2017","journal-title":"Drug Discov. Ther."},{"issue":"3","key":"10.1016\/j.cnp.2021.10.004_b0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1517\/14740338.6.3.241","article-title":"The safety of levetiracetam","volume":"6","author":"Sirsi","year":"2007","journal-title":"Expert. Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.cnp.2021.10.004_b0085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.seizure.2014.02.003","article-title":"measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs)","volume":"23","author":"Stepanova","year":"2014","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.cnp.2021.10.004_b0090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/01.wnl.0000324604.11657.c6","article-title":"Levetiracetam as a possible cause of fulminant liver failure","volume":"71","author":"Tan","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.cnp.2021.10.004_b0095","first-page":"29","article-title":"Coma after levetiracetam overdose","volume":"20","author":"Vellinga","year":"2015","journal-title":"Neth. J. Crit. Care"},{"issue":"5","key":"10.1016\/j.cnp.2021.10.004_b0100","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.seizure.2009.01.006","article-title":"Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves","volume":"18","author":"Vulliemoz","year":"2009","journal-title":"Seizure"}],"container-title":["Clinical Neurophysiology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2467981X21000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2467981X21000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T02:03:58Z","timestamp":1762826638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2467981X21000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"alternative-id":["S2467981X21000469"],"URL":"https:\/\/doi.org\/10.1016\/j.cnp.2021.10.004","relation":{},"ISSN":["2467-981X"],"issn-type":[{"type":"print","value":"2467-981X"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifocal myoclonus as a presentation of levetiracetam toxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cnp.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}